Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy--an extended haplotype of genetic variants increases risk in indinavir treatment.

Journal of hepatology - 1 May 2009

Lankisch Tim O, Behrens Georg, Ehmer Ursula, Möbius Ulrike, Rockstroh Juergen, Wehmeier Michael, Kalthoff Sandra, Freiberg Nicole, Manns Michael P, Schmidt Reinhold E, Strassburg Christian P

Abstract excerpt

BACKGROUND/AIMS: Gilbert's syndrome is a frequent genetic conjugation abnormality associated with adverse drug effects. Genetic UDP glucuronosyltransferase (UGT)1A gene variants can influence gene transcription, inducibility and glucuronidation activity. Protease inhibitors used in human immunodeficiency virus (HIV) infection and chronic viral hepatitis can inhibit UGTs. Indinavir (IDV) can lead to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Case-Control Studies
Share to Gilbert Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Haplotypes

Share to Hyperbilirubinemia

Share to Indinavir

Share to Predictive Value of Tests

Share to Protease Inhibitors

Source

Identifiers

PMID: 19303655
DOI: 10.1016/j.jhep.2008.12.030

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy--an extended haplotype of genetic variants increases risk in indinavir treatment.PMID 19303655Read ↗

Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.Semantic proximity Read ↗

Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.Semantic proximity Read ↗

Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.Semantic proximity Read ↗

Pharmacogenetics of Gilbert's syndrome.Semantic proximity Read ↗

Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.Semantic proximity Read ↗

Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg?Semantic proximity Read ↗

Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.Semantic proximity Read ↗

Rapid allelic discrimination by TaqMan PCR for the detection of the Gilbert's syndrome marker UGT1A1*28.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.Semantic proximity Read ↗

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.Semantic proximity Read ↗

The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.Semantic proximity Read ↗

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.